Efficacy and tolerability of trazodone retard monotherapy: results of the Serbian non-interventional study.
Int J Psychiatry Clin Pract
; 20(3): 133-40, 2016 Sep.
Article
en En
| MEDLINE
| ID: mdl-27335239
ABSTRACT
OBJECTIVE:
Trazodone is an effective antidepressant. The present study was designed as a non-interventional open-label, multi-centre, post-marketing study. The aim of the study was to evaluate the therapeutic effectiveness and tolerability of trazodone retard formulation (Trittico(®) retard) in everyday clinical practice.METHODS:
Two hundred and forty-two patients with depressive disorder from 19 different centres were included in the study. The antidepressant and anxyolitic effects were assessed using Hamilton anxiety rating scale 14 items version, Hamilton depression rating scale 14 items version and Clinical Global Impression Severity scale.RESULTS:
After only two weeks of therapy, a statistically significant improvement in the HAM-D score, was observed. This observation was maintained over the whole study period, up to the day 56.CONCLUSIONS:
Our study points toward clinical effectiveness of the prolonged-release formulation of trazodone in the treatment of unselected depressed patients in real-world practice.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Trazodona
/
Evaluación de Resultado en la Atención de Salud
/
Inhibidores Selectivos de la Recaptación de Serotonina
Tipo de estudio:
Clinical_trials
/
Observational_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Europa
Idioma:
En
Revista:
Int J Psychiatry Clin Pract
Año:
2016
Tipo del documento:
Article